---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-067471"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T19:43:02.028842+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Amylyx appoints Dr. Bernhardt Zeiher to board, fills Class I director vacancy

## Summary
- Appointed March 14, 2024 as Class I director; term expires at 2025 annual meeting.
- Also named to Nominating and Corporate Governance Committee, replacing Paul Fonteyne.
- Zeiher was Chief Medical Officer at Astellas Pharma from 2018-2022; joined Entrada Therapeutics board in 2023.
- Receives initial option grant (lesser of $570K value or 50K shares); 1/3 vests at one year, remainder over two years.
- Annual retainer of $45,000 plus $5,000 for Nominating Committee service; eligible for annual option grants.

## SEC filing metadata
- accession: 0001193125-24-067471
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000119312524067471/0001193125-24-067471-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000119312524067471/d789002d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-067471
- JSON: https://secwatch.observer/filing/0001193125-24-067471.json
- Plain text: https://secwatch.observer/filing/0001193125-24-067471.txt

## Key facts
- Executive change
  Bernhardt Zeiher was appointed as Class I Director at Amylyx Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Class I Director
  source text: On March 14, 2024 (the “Effective Date”), the Board of Directors (the “Board”) of Amylyx Pharmaceuticals, Inc. (the “Company”) appointed Bernhardt Zeiher, MD, FCCP, FACP to fill a vacancy on the Board as a Class I director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658551/000119312524067471/0001193125-24-067471-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.